Botulinum Toxin Type A for refractory trigeminal neuralgia in older patients: a better therapeutic effect

References

• Headache Classification Committee of the International Headache Society (IHS). International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629–808.
   Google Scholar
• Cruccu G, Gronseth G, Alksne J, et al.; for American Academy of Neurology Society; for European Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013–1028. doi:10.1111/j.1468-1331.2008.02131.x18721143
   PubMed Web of Science ®Google Scholar
• Wu CJ, Shen JH, Chen Y, Lian YJ. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm. Turk Neurosurg. 2011;21(4):625–629.22194126
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. doi:10.1177/033310241036467620647170
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814. doi:10.1177/033310241036467720647171
   PubMed Web of Science ®Google Scholar
• Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P. Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Rev Neurother. 2016;16(10):1217–1227. doi:10.1080/14737175.2016.120097327310178
   PubMed Web of Science ®Google Scholar
• Sandrini G, De Icco R, Tassorelli C, Smania N, Tamburin S. Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain. 2017;18(1):38. doi:10.1186/s10194-017-0744-z28324318
   PubMed Web of Science ®Google Scholar
• Micheli F, Scorticati MC, Raina G. Beneficial effects of Botulinum Toxin Type A for patients with painful tic convulsif. Clin Neuropharmacol. 2002;25(5):260–262. doi:10.1097/00002826-200209000-0000612410057
   PubMed Web of Science ®Google Scholar
• Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002;3(1):21–27.14622850
   PubMed Web of Science ®Google Scholar
• Allam N, Brasil-Neto JP, Brown G, Tomaz C. Injections of botulinum Toxin Type A produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005;21(2):182–184. doi:10.1097/00002508-200503000-0001015722812
   PubMed Web of Science ®Google Scholar
• Türk U, Ilhan S, Alp R, Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005;28(4):161–162. doi:10.1097/01.wnf.0000172497.24770.b016062093
   PubMed Web of Science ®Google Scholar
• Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of Botulinum-A Toxin treatment of trigeminal neuralgia. Neurology. 2005;65(8):1306–1308. doi:10.1212/01.wnl.0000180940.98815.7416247065
   PubMed Web of Science ®Google Scholar
• Zuniga C, Diaz S, Piedimonte F, Micheli F. Beneficial effects of Botulinum Toxin Type A in trigeminal neuralgia. Arq Neuropsiquiatr. 2008;66(3A):500–503. doi:10.1590/S0004-282X200800040001218813708
   PubMed Web of Science ®Google Scholar
• Ngeow WC, Nair R. Injection of Botulinum Toxin Type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e47–e50. doi:10.1016/j.tripleo.2009.03.021
   PubMed Web of Science ®Google Scholar
• Bohluli B, Motamedi MH, Bagheri SC, et al. Use of Botulinum Toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral PatholOral Radiol Endod. 2011;111(1):47–50. doi:10.1016/j.tripleo.2010.04.043
   Web of Science ®Google Scholar
• Lunde HM, Torkildsen O, Bo L, et al. Botulinum toxin as monotherapy in symptomatic trigeminal neuralgia. Headache. 2016;56(6):1035–1039. doi:10.1111/head.1279126992044
   PubMed Web of Science ®Google Scholar
• Wu CJ, Lian YJ, Zheng YK, et al. Botulinum Toxin Type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443–450. doi:10.1177/033310241244172122492424
   PubMed Web of Science ®Google Scholar
• Zhang H, Lian Y, Ma Y, et al. Two doses of Botulinum Toxin Type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65. doi:10.1186/1129-2377-15-6525263254
   PubMed Web of Science ®Google Scholar
• Zhang H, Lian Y, Xie N, Chen C, Zheng Y. Single-dose botulinum Toxin Type A compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study. J Headache Pain. 2017;18(1):81. doi:10.1186/s10194-017-0793-328799056
   PubMed Web of Science ®Google Scholar
• Li S, Lian YJ, Chen Y, et al. Therapeutic effect of Botulinum Toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. J Headache Pain. 2014;15:43. doi:10.1186/1129-2377-15-4324952600
   PubMed Web of Science ®Google Scholar
• Cruccu G, Truini A. Refractory trigeminal neuralgia. Non-surgical treatment options. CNS Drugs. 2013;27(2):91–96. doi:10.1007/s40263-012-0023-023225488
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121. doi:10.1016/j.jpain.2007.09.00518055266
   PubMed Web of Science ®Google Scholar
• Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin a in postherpetic neuralgia: a parallel, randomized, double-blind,single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–864. doi:10.1097/AJP.0b013e31827a72d223370074
   PubMed Web of Science ®Google Scholar
• Chen WT, Yuan RY, Chiang SC, et al. OnabotulinumtoxinA improvestactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013;29(4):305–310. doi:10.1097/AJP.0b013e318255c13223462284
   PubMed Web of Science ®Google Scholar
• Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–1478. doi:10.1212/WNL.0b013e3181a9fad119246421
   PubMed Web of Science ®Google Scholar
• Taylor M, Silva S, Cottrell C. Botulinum Toxin Type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Headache. 2008;48(10):1476–1481. doi:10.1111/j.1526-4610.2008.01089.x19076646
   PubMed Web of Science ®Google Scholar
• Bahgat D, Ray DK, Raslan AM, McCartney S, Burchiel KJ. Trigeminal neuralgia in young adults. J Neurosurg. 2011;114(5):1306–1331. doi:10.3171/2010.10.JNS1078121128738
   PubMed Web of Science ®Google Scholar
• Phan K, Rao PJ, Dexter M. Microvascular decompression for elderly patients with trigeminal neuralgia. J Clin Neurosci. 2016;29:7–14. doi:10.1016/j.jocn.2015.11.02726944213
   PubMed Web of Science ®Google Scholar
• Chakravarthi PS, Ghanta R, Kattimani V. Microvascular decompression treatment for trigeminal neuralgia. J Craniofac Surg. 2011;22(3):894–898. doi:10.1097/SCS.0b013e31821a07b721558885
   PubMed Web of Science ®Google Scholar
• Luvisetto S, Gazerani P, Cianchetti C, Pavone F. Botulinum Toxin Type A as a therapeutic agent against headache and related disorders. Toxins. 2015;7(9):3818–3844. doi:10.3390/toxins709381826404377
   PubMed Web of Science ®Google Scholar
• Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31(15):1542–1548. doi:10.1177/033310241142461921960648
   PubMed Web of Science ®Google Scholar